ArticleInternational journal of hematology2021

Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVOR.

Naoki Takezako et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.